Alnylam’s heart drug outlook dimmed as rival eplontersen fails at ESC Congress
The European Society of Cardiology Congress in Munich is a focal point for Alnylam Pharmaceuticals as it seeks clarity on the future of its two ATTR-CM programs.
Data presented by AstraZeneca and Ionis Pharmaceuticals revealed that their candidate eplontersen did not significantly reduce cardiovascular deaths or recurrent events compared with placebo.
The unexpected negative readout raises doubts about the competitive landscape for Alnylam’s own heart‑failure drugs, prompting caution among investors and cardiologists.
Stakeholders will be watching closely for any additional data or strategic moves from Alnylam in the weeks following the conference.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Alnylam’s heart drug troubles take center stage at a cardiology conference”
read at STAT ↗
comments(0)
5-min edit window · permanent after that